Plasmatic and urinary 5-hydroxyindolacetic acid measurements in patients with midgut neuroendocrine tumors: a GTE study.

Date publication

décembre 2020

Journal

The Journal of clinical endocrinology and metabolism

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CADIOT Guillaume

Tous les auteurs :
de Mestier L, Savagner F, Brixi H, Do Cao C, Dominguez-Tinajero S, Roquin G, Goichot B, Hentic O, Dubreuil O, Hautefeuille V, Walter T, Cadiot G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33382891

Résumé

Although 24-hour urinary 5-hydroxyindolacetic acid (24u5HIAA) is a key biomarker in midgut neuroendocrine tumors (NET), it may be inaccurate and inconvenient. We compared the diagnostic performances of 24u5HIAA, overnight urinary 5HIAA (Ou5HIAA) and plasmatic 5HIAA (p5HIAA) in midgut NET.

Mots clés

5-hydroxyindolacetic acid, biomarker, carcinoid syndrome, diagnosis, neuroendocrine tumors

Référence

J Clin Endocrinol Metab. 2020 Dec 31;: